Merck’s “VIGORous” Defense Of Vioxx; Novartis, Wyeth Studies Might Help
Executive Summary
Merck still believes that the initial cardiovascular safety signal seen for Vioxx can be explained by a cardioprotective effect from naproxen, the company said during an Oct. 13 press conference in New York City
You may also be interested in...
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra
FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review